JP2014515028A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014515028A5 JP2014515028A5 JP2014508146A JP2014508146A JP2014515028A5 JP 2014515028 A5 JP2014515028 A5 JP 2014515028A5 JP 2014508146 A JP2014508146 A JP 2014508146A JP 2014508146 A JP2014508146 A JP 2014508146A JP 2014515028 A5 JP2014515028 A5 JP 2014515028A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- individual
- administered
- nanoparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 91
- 239000002105 nanoparticle Substances 0.000 claims description 43
- 210000004204 blood vessel Anatomy 0.000 claims description 35
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 21
- 102000009027 Albumins Human genes 0.000 claims description 17
- 108010088751 Albumins Proteins 0.000 claims description 17
- 238000002347 injection Methods 0.000 claims description 13
- 239000007924 injection Substances 0.000 claims description 13
- 230000002792 vascular Effects 0.000 claims description 12
- 210000001367 artery Anatomy 0.000 claims description 11
- 206010016654 Fibrosis Diseases 0.000 claims description 10
- 230000004761 fibrosis Effects 0.000 claims description 10
- 210000001519 tissue Anatomy 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 238000007634 remodeling Methods 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 210000004379 membrane Anatomy 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 5
- 238000013152 interventional procedure Methods 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 4
- 229960002930 sirolimus Drugs 0.000 claims description 4
- 210000001147 pulmonary artery Anatomy 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 2
- 238000002399 angioplasty Methods 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 210000001627 cerebral artery Anatomy 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 210000004351 coronary vessel Anatomy 0.000 claims description 2
- 210000002414 leg Anatomy 0.000 claims description 2
- 201000002818 limb ischemia Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 210000002254 renal artery Anatomy 0.000 claims description 2
- 210000003462 vein Anatomy 0.000 claims description 2
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 208000024980 claudication Diseases 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 claims 1
- 229940041033 macrolides Drugs 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 40
- 208000030175 lameness Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161518084P | 2011-04-28 | 2011-04-28 | |
| US61/518,084 | 2011-04-28 | ||
| US201161557851P | 2011-11-09 | 2011-11-09 | |
| US61/557,851 | 2011-11-09 | ||
| PCT/US2012/035626 WO2012149451A1 (en) | 2011-04-28 | 2012-04-27 | Intravascular delivery of nanoparticle compositions and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016196955A Division JP6196719B2 (ja) | 2011-04-28 | 2016-10-05 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014515028A JP2014515028A (ja) | 2014-06-26 |
| JP2014515028A5 true JP2014515028A5 (https=) | 2015-06-18 |
| JP6038123B2 JP6038123B2 (ja) | 2016-12-07 |
Family
ID=47072793
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014508146A Active JP6038123B2 (ja) | 2011-04-28 | 2012-04-27 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
| JP2016196955A Active JP6196719B2 (ja) | 2011-04-28 | 2016-10-05 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
| JP2017157942A Active JP6427641B2 (ja) | 2011-04-28 | 2017-08-18 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
| JP2018203038A Pending JP2019011378A (ja) | 2011-04-28 | 2018-10-29 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016196955A Active JP6196719B2 (ja) | 2011-04-28 | 2016-10-05 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
| JP2017157942A Active JP6427641B2 (ja) | 2011-04-28 | 2017-08-18 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
| JP2018203038A Pending JP2019011378A (ja) | 2011-04-28 | 2018-10-29 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US9061014B2 (https=) |
| EP (1) | EP2701731B1 (https=) |
| JP (4) | JP6038123B2 (https=) |
| KR (3) | KR101970342B1 (https=) |
| CN (3) | CN109172809A (https=) |
| AU (2) | AU2012249371B2 (https=) |
| BR (1) | BR112013027674A2 (https=) |
| CA (2) | CA3063641A1 (https=) |
| ES (1) | ES2819204T3 (https=) |
| IL (2) | IL229041B (https=) |
| MX (1) | MX354216B (https=) |
| SG (2) | SG10201606406PA (https=) |
| WO (1) | WO2012149451A1 (https=) |
| ZA (1) | ZA201307875B (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6302875B1 (en) | 1996-10-11 | 2001-10-16 | Transvascular, Inc. | Catheters and related devices for forming passageways between blood vessels or other anatomical structures |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US10441747B2 (en) | 2002-01-22 | 2019-10-15 | Mercator Medsystems, Inc. | Methods and systems for inhibiting vascular inflammation |
| US7617005B2 (en) | 2002-04-08 | 2009-11-10 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
| US9636174B2 (en) | 2002-04-08 | 2017-05-02 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
| US20080213331A1 (en) | 2002-04-08 | 2008-09-04 | Ardian, Inc. | Methods and devices for renal nerve blocking |
| US8150519B2 (en) | 2002-04-08 | 2012-04-03 | Ardian, Inc. | Methods and apparatus for bilateral renal neuromodulation |
| US20070129761A1 (en) | 2002-04-08 | 2007-06-07 | Ardian, Inc. | Methods for treating heart arrhythmia |
| US20070135875A1 (en) | 2002-04-08 | 2007-06-14 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
| JP5219518B2 (ja) | 2004-12-09 | 2013-06-26 | ザ ファウンドリー， エルエルシー | 大動脈弁修復 |
| AU2012201568B2 (en) * | 2005-02-18 | 2014-07-31 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| SI1853250T1 (sl) | 2005-02-18 | 2012-01-31 | Abraxis Bioscience Llc | Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| KR101420445B1 (ko) | 2005-08-31 | 2014-07-16 | 아브락시스 바이오사이언스, 엘엘씨 | 수 난용성 제약학적 약제 및 항균제를 포함하는 조성물 |
| EP3470071A1 (en) | 2006-12-14 | 2019-04-17 | Abraxis BioScience, LLC | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| HRP20192259T1 (hr) | 2009-04-15 | 2020-03-06 | Abraxis Bioscience, Llc | Pripravci nanočestica bez priona i metode njihove proizvodnje |
| WO2010124120A1 (en) | 2009-04-22 | 2010-10-28 | Mercator Medsystems, Inc. | Use of guanethidine for treating hypertension by local vascular delivery |
| CA3051495A1 (en) | 2010-03-26 | 2011-09-29 | Abraxis Bioscience, Llc | Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma |
| NZ717490A (en) | 2010-03-29 | 2017-12-22 | Abraxis Bioscience Llc | Methods of treating cancer |
| KR20130028727A (ko) | 2010-03-29 | 2013-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 약물 전달 및 유효성 향상 방법 |
| BR112012030909A2 (pt) | 2010-06-04 | 2020-08-18 | Abraxis Bioscience, Llc | métodos de tratamento de câncer pancreático |
| US20120259269A1 (en) | 2011-04-08 | 2012-10-11 | Tyco Healthcare Group Lp | Iontophoresis drug delivery system and method for denervation of the renal sympathetic nerve and iontophoretic drug delivery |
| JP6038123B2 (ja) | 2011-04-28 | 2016-12-07 | アブラクシス バイオサイエンス， エルエルシー | ナノ粒子組成物の脈管内送達およびそれらの使用 |
| JP6216721B2 (ja) | 2011-12-14 | 2017-10-18 | アブラクシス バイオサイエンス， エルエルシー | 粒子を凍結乾燥または凍結するためのポリマー賦形剤の使用 |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| DK2964329T3 (da) | 2013-03-08 | 2020-03-16 | Univ California | Polyphosphat-funktionaliserede uorganiske nanopartikler som hæmostatiske sammensætninger og anvendelsesfremgangsmåder |
| EP3698784A1 (en) | 2013-03-12 | 2020-08-26 | Abraxis BioScience, LLC | Methods of treating lung cancer |
| EP2968191B1 (en) | 2013-03-14 | 2021-06-16 | Abraxis BioScience, LLC | Methods of treating bladder cancer |
| US10550187B2 (en) | 2014-10-24 | 2020-02-04 | Incept, Llc | Extra luminal scaffold |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| PL3998069T3 (pl) | 2015-06-29 | 2025-03-31 | Abraxis Bioscience, Llc | Nanocząsteczki zawierające syrolimus i albuminę do zastosowania w leczeniu nowotworów z komórek nabłonkowatych |
| WO2018057788A1 (en) * | 2016-09-22 | 2018-03-29 | Mercator Medsystems, Inc. | Treatment of restenosis using temsirolimus |
| EP3518923A4 (en) * | 2016-09-28 | 2020-06-17 | Abraxis BioScience, LLC | METHOD FOR TREATING MITOCHONDRIAL AND METABOLIC DISORDERS |
| AU2018272061A1 (en) | 2017-05-26 | 2020-01-02 | Mercator Medsystems, Inc. | Combination therapy for treatment of restenosis |
| US11116561B2 (en) | 2018-01-24 | 2021-09-14 | Medtronic Ardian Luxembourg S.A.R.L. | Devices, agents, and associated methods for selective modulation of renal nerves |
| CN212631328U (zh) | 2018-03-14 | 2021-03-02 | 墨卡托医疗系统公司 | 用于局部药物递送的医疗器械 |
| IL277402B1 (en) | 2018-03-20 | 2026-04-01 | Abraxis Bioscience Llc | Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin |
| JP7335123B2 (ja) * | 2019-10-07 | 2023-08-29 | 株式会社日本触媒 | 樹脂組成物、硬化性組成物、塗膜付き物品、塗膜付き物品の製造方法、コーティング剤及び積層塗膜付き基材の製造方法 |
| JP7832108B2 (ja) | 2019-10-28 | 2026-03-17 | アブラクシス バイオサイエンス， エルエルシー | アルブミンおよびラパマイシンの医薬組成物 |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5997904A (en) | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| BR9405798A (pt) | 1993-02-22 | 1995-12-12 | Vivorx Pharmaceuticals Inc | Métodos para liberação in vivo de material biológico e composições úteis dos mesmos |
| US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US5362478A (en) | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6528067B1 (en) | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US5650156A (en) | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
| US6565842B1 (en) | 1995-06-07 | 2003-05-20 | American Bioscience, Inc. | Crosslinkable polypeptide compositions |
| US20070092563A1 (en) | 1996-10-01 | 2007-04-26 | Abraxis Bioscience, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030199425A1 (en) | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| ITMI20001107A1 (it) | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
| CN1331321A (zh) | 2000-06-30 | 2002-01-16 | 上海博德基因开发有限公司 | 一种新的多肽——人丝/苏氨酸蛋白激酶16.17和编码这种多肽的多核苷酸 |
| ATE481097T1 (de) * | 2001-01-16 | 2010-10-15 | Vascular Therapies Llc | Implantierbare vorrichtung enthaltend resorbierbares matrixmaterial und antiproliferative wirkstoffe zur vorbeugung oder behandlung von versagen vaskulärer hämodialysezugänge und anderer vaskulärer transplantate |
| US6547303B1 (en) | 2001-08-13 | 2003-04-15 | Johnson Controls Technology Company | Pivoting seating system |
| US6860867B2 (en) | 2001-09-20 | 2005-03-01 | The Regents Of The University Of California | Method of interventional surgery |
| US7744584B2 (en) | 2002-01-22 | 2010-06-29 | Mercator Medsystems, Inc. | Methods and kits for volumetric distribution of pharmaceutical agents via the vascular adventitia and microcirculation |
| US20030171734A1 (en) | 2002-01-22 | 2003-09-11 | Endobionics, Inc. | Methods and kits for delivering pharmaceutical agents into the coronary vascular adventitia |
| US20060189941A1 (en) * | 2002-01-22 | 2006-08-24 | Mercator Medsystems, Inc. | Methods and kits for volumetric distribution of pharmaceutical agents via the vascular adventitia and microcirculation |
| US20030207907A1 (en) | 2002-05-03 | 2003-11-06 | Iversen Patrick L. | Delivery of microparticle-conjugated drugs for inhibition of stenosis |
| DE10244847A1 (de) * | 2002-09-20 | 2004-04-01 | Ulrich Prof. Dr. Speck | Medizinische Vorrichtung zur Arzneimittelabgabe |
| KR20050084599A (ko) * | 2002-09-26 | 2005-08-26 | 안지오테크 인터내셔날 아게 | 혈관주위 랩 |
| CN103405405A (zh) | 2002-12-09 | 2013-11-27 | 阿布拉西斯生物科学有限责任公司 | 组合物和传递药剂的方法 |
| US20040213770A1 (en) | 2003-04-22 | 2004-10-28 | Endobionics, Inc. | Methods and systems for treating ischemic cardiac and other tissues |
| US8003122B2 (en) * | 2004-03-31 | 2011-08-23 | Cordis Corporation | Device for local and/or regional delivery employing liquid formulations of therapeutic agents |
| WO2005112569A2 (en) | 2004-05-13 | 2005-12-01 | Medtronic Vascular, Inc. | Methods for compounding and delivering a therapeutic agent to the adventitia of a vessel |
| AU2006249235B2 (en) * | 2004-05-14 | 2010-11-11 | Abraxis Bioscience, Llc | Sparc and methods of use thereof |
| US7727554B2 (en) | 2004-12-21 | 2010-06-01 | Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center | Sustained-release nanoparticle compositions and methods for using the same |
| SI1853250T1 (sl) | 2005-02-18 | 2012-01-31 | Abraxis Bioscience Llc | Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US20080214595A1 (en) | 2005-05-16 | 2008-09-04 | Seigo Izumo | Use Of Rapamycin Derivatives For The Treatment And/Or Prevention Of Cardiovas Cular Disorders |
| EP1901680B1 (en) | 2005-06-21 | 2015-04-15 | Shire Regenerative Medicine, Inc. | Crypreservation of biocompatible material |
| KR101420445B1 (ko) | 2005-08-31 | 2014-07-16 | 아브락시스 바이오사이언스, 엘엘씨 | 수 난용성 제약학적 약제 및 항균제를 포함하는 조성물 |
| AU2006284657B2 (en) | 2005-08-31 | 2012-07-19 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| US20080145439A1 (en) * | 2006-07-31 | 2008-06-19 | Neurosystec Corporation | Nanoparticle drug formulations |
| US20100112077A1 (en) | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
| EP3470071A1 (en) | 2006-12-14 | 2019-04-17 | Abraxis BioScience, LLC | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| WO2008109163A1 (en) | 2007-03-07 | 2008-09-12 | Abraxis Bioscience, Llc. | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| CN101730526A (zh) * | 2007-03-07 | 2010-06-09 | 阿布拉科斯生物科学有限公司 | 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒 |
| US20100166869A1 (en) * | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
| US9044385B2 (en) * | 2007-05-16 | 2015-06-02 | Abbott Cardiovascular Systems Inc. | Therapeutic compositions for targeted vessel delivery |
| JP5579057B2 (ja) | 2007-06-01 | 2014-08-27 | アブラクシス バイオサイエンス， エルエルシー | 再発性癌の処置のための方法および組成物 |
| ES2718612T3 (es) * | 2007-12-20 | 2019-07-03 | Evonik Corp | Procedimiento para preparar micropartículas que tienen un bajo volumen de disolvente residual |
| MX2010011165A (es) | 2008-04-10 | 2011-02-22 | Abraxis Bioscience Llc | Composiciones de derivados de taxano hidrofobos y sus usos. |
| NZ593343A (en) | 2008-12-11 | 2013-04-26 | Abraxis Bioscience Llc | Combination cancer treatment conprising Abraxane and an inflamatory inhibitor |
| CN102427728A (zh) | 2009-03-13 | 2012-04-25 | 阿布拉科斯生物科学有限公司 | 用硫代秋水仙碱衍生物进行联合治疗 |
| EP2416650B1 (en) | 2009-04-10 | 2020-02-26 | Abraxis BioScience, LLC | Nanoparticle formulations and uses therof |
| HRP20192259T1 (hr) | 2009-04-15 | 2020-03-06 | Abraxis Bioscience, Llc | Pripravci nanočestica bez priona i metode njihove proizvodnje |
| WO2010124120A1 (en) * | 2009-04-22 | 2010-10-28 | Mercator Medsystems, Inc. | Use of guanethidine for treating hypertension by local vascular delivery |
| PL2470173T3 (pl) | 2009-08-25 | 2016-11-30 | Leczenie skojarzone nanocząstkowymi kompozycjami taksanu i inhibitorów hedgehog | |
| CA3051495A1 (en) | 2010-03-26 | 2011-09-29 | Abraxis Bioscience, Llc | Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma |
| KR20130028727A (ko) | 2010-03-29 | 2013-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 약물 전달 및 유효성 향상 방법 |
| NZ717490A (en) | 2010-03-29 | 2017-12-22 | Abraxis Bioscience Llc | Methods of treating cancer |
| EP3085387A1 (en) * | 2010-04-26 | 2016-10-26 | Abraxis BioScience, LLC | Sparc binding antibodies and uses thereof |
| WO2011153009A1 (en) | 2010-06-02 | 2011-12-08 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
| BR112012030909A2 (pt) | 2010-06-04 | 2020-08-18 | Abraxis Bioscience, Llc | métodos de tratamento de câncer pancreático |
| WO2011156119A1 (en) | 2010-06-07 | 2011-12-15 | Abraxis Bioscience, Llc | Combination therapy methods for treating proliferative diseases |
| JP6038123B2 (ja) | 2011-04-28 | 2016-12-07 | アブラクシス バイオサイエンス， エルエルシー | ナノ粒子組成物の脈管内送達およびそれらの使用 |
| JP6216721B2 (ja) | 2011-12-14 | 2017-10-18 | アブラクシス バイオサイエンス， エルエルシー | 粒子を凍結乾燥または凍結するためのポリマー賦形剤の使用 |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US20140186447A1 (en) | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
| US20140199404A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
| EP3698784A1 (en) | 2013-03-12 | 2020-08-26 | Abraxis BioScience, LLC | Methods of treating lung cancer |
| CN105209035A (zh) | 2013-03-13 | 2015-12-30 | 阿布拉科斯生物科学有限公司 | 治疗儿童实体瘤的方法 |
| EP2968191B1 (en) | 2013-03-14 | 2021-06-16 | Abraxis BioScience, LLC | Methods of treating bladder cancer |
| US20170202782A1 (en) | 2014-04-06 | 2017-07-20 | Abraxis Bioscience, Llc | Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer |
| US20180064679A1 (en) | 2015-03-05 | 2018-03-08 | Abraxis Bioscience, Llc | Method for treating cancer based on level of glucocorticoid receptor |
| HK1247093A1 (zh) | 2015-06-29 | 2018-09-21 | 阿布拉科斯生物科学有限公司 | 使用纳米颗粒mtor抑制剂联合疗法治疗实体瘤的方法 |
| US20180177771A1 (en) | 2015-06-29 | 2018-06-28 | Abraxis Bioscience, Llc | Biomarkers for nanoparticle compositions |
| PL3998069T3 (pl) | 2015-06-29 | 2025-03-31 | Abraxis Bioscience, Llc | Nanocząsteczki zawierające syrolimus i albuminę do zastosowania w leczeniu nowotworów z komórek nabłonkowatych |
| US20180256551A1 (en) | 2015-06-29 | 2018-09-13 | Abraxis Bioscience, Llc | Methods of treating hematological malignancy using nanoparticle mtor inhibitor combination therapy |
| US20170181988A1 (en) | 2015-12-23 | 2017-06-29 | Cipla Limited | Methods for the treatment of bladder cancer |
-
2012
- 2012-04-27 JP JP2014508146A patent/JP6038123B2/ja active Active
- 2012-04-27 KR KR1020137031161A patent/KR101970342B1/ko active Active
- 2012-04-27 CA CA3063641A patent/CA3063641A1/en not_active Abandoned
- 2012-04-27 KR KR1020207012800A patent/KR20200051841A/ko not_active Ceased
- 2012-04-27 CN CN201810882369.8A patent/CN109172809A/zh active Pending
- 2012-04-27 CN CN201811222358.3A patent/CN109288789A/zh active Pending
- 2012-04-27 US US14/113,568 patent/US9061014B2/en active Active
- 2012-04-27 ES ES12777153T patent/ES2819204T3/es active Active
- 2012-04-27 MX MX2013012458A patent/MX354216B/es active IP Right Grant
- 2012-04-27 EP EP12777153.3A patent/EP2701731B1/en active Active
- 2012-04-27 SG SG10201606406PA patent/SG10201606406PA/en unknown
- 2012-04-27 AU AU2012249371A patent/AU2012249371B2/en active Active
- 2012-04-27 BR BR112013027674A patent/BR112013027674A2/pt not_active Application Discontinuation
- 2012-04-27 CN CN201280032010.2A patent/CN103648521A/zh active Pending
- 2012-04-27 SG SG2013079264A patent/SG194623A1/en unknown
- 2012-04-27 KR KR1020197010659A patent/KR102108959B1/ko active Active
- 2012-04-27 WO PCT/US2012/035626 patent/WO2012149451A1/en not_active Ceased
- 2012-04-27 CA CA2834040A patent/CA2834040C/en active Active
-
2013
- 2013-10-22 ZA ZA2013/07875A patent/ZA201307875B/en unknown
- 2013-10-24 IL IL229041A patent/IL229041B/en active IP Right Grant
-
2015
- 2015-05-15 US US14/714,131 patent/US9884013B2/en not_active Expired - Fee Related
-
2016
- 2016-10-05 JP JP2016196955A patent/JP6196719B2/ja active Active
-
2017
- 2017-08-18 JP JP2017157942A patent/JP6427641B2/ja active Active
- 2017-09-06 AU AU2017225031A patent/AU2017225031B2/en active Active
- 2017-12-21 US US15/851,478 patent/US10258565B2/en active Active
-
2018
- 2018-10-29 JP JP2018203038A patent/JP2019011378A/ja active Pending
-
2019
- 2019-02-25 US US16/284,995 patent/US20190183789A1/en not_active Abandoned
-
2020
- 2020-01-28 IL IL272313A patent/IL272313A/en unknown
- 2020-06-12 US US16/900,565 patent/US20200306180A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014515028A5 (https=) | ||
| JP2017002083A5 (https=) | ||
| KR102108959B1 (ko) | 나노입자 조성물의 혈관내 전달 및 그의 용도 | |
| HRP20221100T1 (hr) | Stabilna parenteralna formulacija nimopidina | |
| Liu et al. | Additive benefit of glycoprotein IIb/IIIa inhibition and adjunctive thrombus aspiration during primary coronary intervention: results of the Initial Thrombosuction and Tirofiban Infusion (ITTI) trial | |
| JP2020521755A5 (https=) | ||
| JP2010530001A5 (https=) | ||
| de Gregorio et al. | Citalopram-induced long QT syndrome and torsade de pointes: role for concomitant therapy and disease | |
| Jin et al. | The myocardial protective effects of adenosine pretreatment in children undergoing cardiac surgery: a randomized controlled clinical trial | |
| Ellenberger et al. | Cardiovascular collapse due to massive pulmonary thromboembolism during orthotopic liver transplantation | |
| Kim et al. | Intercoronary communication between the circumflex and right coronary arteries coexisted with coronary vasospasm | |
| CN116603116B (zh) | 黄芩苷-铜复合纳米涂层鞘管及其制备方法与用途 | |
| Turan et al. | Effectiveness of sublingual nitroglycerin before puncture compared with conventional intra-arterial nitroglycerin in transradial procedures: A randomized trial | |
| Koutouzis et al. | Percutaneous coronary intervention facilitated by extracorporeal membrane oxygenation support in a patient with cardiogenic shock | |
| TWI631944B (zh) | 氯硝柳胺及其衍生物的用途 | |
| JP5589838B2 (ja) | 血管性疾患の予防剤及び／又は治療剤 | |
| Tespili et al. | Life-threatening left main stenosis induced by compression from a dilated pulmonary artery | |
| Soga et al. | Clinical impact of bisoprolol versus carvedilol in patients undergoing femoropopliteal stenting | |
| HRP20200897T1 (hr) | Parenteralna formulacija esmolola | |
| Gülşen et al. | Coronary vasospasm-induced periodic ventricular fibrillation and successful ablation through coronary stenting | |
| Truong et al. | Recurrent intraoperative coronary artery spasm in a patient with coronary artery aneurysm | |
| Ványi et al. | Metoprolol reduces ‘compensatory’coronary blood flow following occlusion of an adjacent branch without altering post-occlusion hyperaemia | |
| Demir et al. | Electroanatomic mapping-guided radiofrequency ablation of multifocal atrial tachycardia in a child/Multifokal atriyal tasikardi'li bir çocugun elektroanatomik haritalama sistemi esliginde radyofrekans kateter ablasyonu | |
| Ngow et al. | Anterior Myocardial Infarction Associated with Myocardial Bridging in a Young Man | |
| Chernomorets et al. | SINGLE-PILL COMBINATION OF PERINDOPRIL ARGININE/INDAPAMIDE DECREASES ARTERIAL STIFFNESS IN THE PATIENTS WITH ARTERIAL HYPERTENSION AND MODERATE CHRONIC KIDNEY DISEASE |